skip to Main Content

New Paradigm for drug toxicity


Introducing NEXEL’s products


Explore Liver Toxicity with Human induced Pluripotent Stem Cell (iPSC)-derived Hepatocytes.

Pharmaceutical industry invests huge amount of money to screen the drug candidates for their toxicity, a key barrier in the development of the new therapies. Liver toxicity has been widely investigated due to the organ’s pivotal roles in our body, including metabolism of exogenous compounds. Currently, primary human hepatocytes (PHHs) have been considered as a ‘gold standard’ for investigation of liver toxicity but has several limitations, including their limited availability as well as variations between the donors.

NEXEL has developed a novel method to differentiate hPSCs into functional hepatocytes to overcome the limitations of PHHs. The Hepatosight®-S guarantees functionality,
reproducibility, availability as well as minimum variations between the batches. We are providing this state-of-the-art technology to our customers at an affordable price.

Applications of Hepatosight®-S

The Hepatosight®-S can be used for various applications as such:

1. Hepatotoxicity testing
2. Drug discovery
3. 3D spheroid culture
4. Development of organ-on-a-chip model


NEXEL provides the Hepatosight®-S in two different formats, 5 million or 10 million cells per vial. The Hepatosight®-S can be used in various types of cell culture plates. Enquire for any technical guidance or questions.

Catalog number H-001
Cryopreserved Hepatosight®-S

Each kit contains

1. Hepatosight®-S Media (HM-001, 70 ml)
2. Hepatosight®-S Supplement (HS-001, 700 µl)
3. User Guide

Quantity ≥ 5 × 106 Viable cells/Vial
Request Quote
Catalog number H-002
Cryopreserved Hepatosight®-S

Each kit contains

1. Hepatosight®-S Media (HM-002, 120 ml)
2. Hepatosight®-S Supplement (HS-002, 1.2 ml)
3. User Guide

Quantity ≥ 1 × 107 Viable cells/Vial
Request Quote
Back To Top